Retro Biosciences, a startup backed by OpenAI CEO Sam Altman, is raising $1 billion in a Series A funding round aimed at extending human lifespans. The company previously secured $180 million in seed funding from Altman and others. Altman’s investment reflects growing interest in leveraging artificial intelligence to enhance longevity. Concurrently, Dario Amodei, CEO of Anthropic, stated that advancements in AI could potentially double human lifespans within five to ten years, particularly in the field of biology. This assertion aligns with the broader trend of integrating AI into health and longevity research, suggesting that significant breakthroughs could occur in the near future.